nach oben

Angiogenesis

Erschienen in:

01.06.2009 | Original Paper

Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature

verfasst von: G-One Ahn, J. Martin Brown

Erschienen in: Angiogenesis | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidence suggests the importance of bone marrow-derived cells for blood vessel formation (neovascularization) in tumors, which can occur in two mechanisms: angiogenesis and vasculogenesis. Angiogenesis results from proliferation and sprouting of existing blood vessels close to the tumor, while vasculogenesis is believed to arise from recruitment of circulating cells, largely derived from the bone marrow, and de novo clonal formation of blood vessels from these cells. Although bone marrow-derived cells are crucial for neovascularization, current evidence suggests a promotional role of these cells on the existing blood vessels rather than de novo neovascularization in tumors. This is believed to be due to the highly proangiogenic features of these cells. The bone marrow-derived cells are heterogeneous, consisting of many different cell types including endothelial progenitor cells, myeloid cells, lymphocytes, and mesenchymal cells. These cells are highly orchestrated under the influence of the specific tumor microenvironment, which varies depending on the tumor type, thereby tightly regulating neovascularization in the tumors. In this review, we highlight some of the recent findings on each of these cell types by outlining some of the essential proangiogenic cytokines that these cells secrete to promote tumor angiogenesis and vasculogenesis.

Rafii S, Lyden D (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9:702–712. doi:10.1038/nm0603-702 PubMedCrossRef

Asahara T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967. doi:10.1126/science.275.5302.964 PubMedCrossRef

Schlaeger TM, Qin Y, Fujiwara Y, Magram J, Sato TN (1995) Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 121:1089–1098PubMed

Motoike T et al (2000) Universal GFP reporter for the study of vascular development. Genesis 28:75–81. doi:10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S PubMedCrossRef

Nolan DJ et al (2007) Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 21:1546–1558. doi:10.1101/gad.436307 PubMedCrossRef

Lyden D et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201. doi:10.1038/nm1101-1194 PubMedCrossRef

Asahara T et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228PubMed

Takahashi T et al (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434–438. doi:10.1038/8462 PubMedCrossRef

Qin G et al (2006) Functional disruption of a4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med 203:153–163. doi:10.1084/jem.20050459 PubMedCrossRef

10.

Ceradini DJ et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864. doi:10.1038/nm1075 PubMedCrossRef

11.

Garcia-Barros M et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159. doi:10.1126/science.1082504 PubMedCrossRef

12.

De Palma M, Venneri MA, Roca C, Naldini L (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9:789–795. doi:10.1038/nm871 PubMedCrossRef

13.

Gothert JR et al (2004) Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 104:1769–1777. doi:10.1182/blood-2003-11-3952 PubMedCrossRef

14.

Purhonen S et al (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 105:6620–6625. doi:10.1073/pnas.0710516105 PubMedCrossRef

15.

Shinde Patil VR et al (2005) Bone marrow-derived lin(−)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. Neoplasia 7:234–240. doi:10.1593/neo.04523 PubMedCrossRef

16.

Machein MR, Renninger S, de Lima-Hahn E, Plate KH (2003) Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13:582–597PubMed

17.

Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193–205. doi:10.1016/j.ccr.2007.11.032 PubMedCrossRef

18.

Kerbel RS et al (2008) Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci USA 105:E54. doi:10.1073/pnas.0804876105 PubMedCrossRef

19.

Salven P et al (2008) EPCs are again claimed to be essential in yet other models despite the irreproducibility of the original experiments introducing them. Proc Natl Acad Sci USA 105:E55. doi:10.1073/pnas.0805971105 CrossRef

20.

Peters BA et al (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261–262. doi:10.1038/nm1200 PubMedCrossRef

21.

Naik RP et al (2008) Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 107:133–138. doi:10.1007/s10549-007-9519-6 PubMedCrossRef

22.

Igreja C et al (2007) Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 92:469–477. doi:10.3324/haematol.10723 PubMedCrossRef

23.

Gao D et al (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319:195–198. doi:10.1126/science.1150224 PubMedCrossRef

24.

Shaked Y et al (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263–273. doi:10.1016/j.ccr.2008.08.001 PubMedCrossRef

25.

Shaked Y et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785–1787. doi:10.1126/science.1127592 PubMedCrossRef

26.

Vidal A et al (2005) p130^Rb2 and p27^kip1 cooperate to control mobilization of angiogenic progenitors from the bone marrow. Proc Natl Acad Sci USA 102:6890–6895. doi:10.1073/pnas.0405823102 PubMedCrossRef

27.

Yamazaki M et al (2008) Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci 99:1131–1138. doi:10.1111/j.1349-7006.2008.00795.x PubMedCrossRef

28.

Furstenberger G et al (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary beast cancer. Br J Cancer 94:524–531. doi:10.1038/sj.bjc.6602952 PubMedCrossRef

29.

Li B et al (2006) VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20:1495–1497. doi:10.1096/fj.05-5137fje PubMedCrossRef

30.

Yang L et al (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421. doi:10.1016/j.ccr.2004.08.031 PubMedCrossRef

31.

Yang L et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23–35. doi:10.1016/j.ccr.2007.12.004 PubMedCrossRef

32.

Lin EA et al (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238–11246. doi:10.1158/0008-5472.CAN-06-1278 PubMedCrossRef

33.

Rohde E et al (2006) Blood monocytes mimic endothelial progenitor cells. Stem Cells 24:357–367. doi:10.1634/stemcells.2005-0072 PubMedCrossRef

34.

Dineen SP et al (2008) Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68:4340–4346. doi:10.1158/0008-5472.CAN-07-6705 PubMedCrossRef

35.

Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826–835. doi:10.1038/nrc925 PubMedCrossRef

36.

Fujiyama S et al (2003) Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 93:980–989. doi:10.1161/01.RES.0000099245.08637.CE PubMedCrossRef

37.

Luttun A et al (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis, and atherosclerosis by anti-Flt1. Nat Med 8:831–840PubMed

38.

Bailey AS et al (2006) Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci USA 103:13156–13161. doi:10.1073/pnas.0604203103 PubMedCrossRef

39.

Li B et al (2009) Low levels of tumor necrosis factor a increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 69:338–348. doi:10.1158/0008-5472.CAN-08-1565 PubMedCrossRef

40.

Bergers G et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744. doi:10.1038/35036374 PubMedCrossRef

41.

Du R et al (2008) HIF1a induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206–220. doi:10.1016/j.ccr.2008.01.034 PubMedCrossRef

42.

Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contribute to skin carcinogenesis. Cell 103:481–490. doi:10.1016/S0092-8674(00)00139-2 PubMedCrossRef

43.

Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623–633PubMed

44.

Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 105:12493–12498. doi:10.1073/pnas.0601807103 CrossRef

45.

Joyce JA et al (2004) Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5:443–453. doi:10.1016/S1535-6108(04)00111-4 PubMedCrossRef

46.

Shojaei F et al (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450:825–831. doi:10.1038/nature06348 PubMedCrossRef

47.

Kujawski M et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367–3377. doi:10.1172/JCI35213 PubMedCrossRef

48.

Sierra JR et al (2008) Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205:1673–1685. doi:10.1084/jem.20072602 PubMedCrossRef

49.

Grunewald M et al (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124:175–189. doi:10.1016/j.cell.2005.10.036 PubMedCrossRef

50.

Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA (2006) Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66:9054–9064. doi:10.1158/0008-5472.CAN-05-3759 PubMedCrossRef

51.

Coussens LM et al (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382–1397. doi:10.1101/gad.13.11.1382 PubMedCrossRef

52.

Heissig B et al (2005) Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9 mediated progenitor cell mobilization. J Exp Med 202:739–750. doi:10.1084/jem.20050959 PubMedCrossRef

53.

Soucek L et al (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211–1218. doi:10.1038/nm1649 PubMedCrossRef

54.

Salgado R et al (2001) Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 4:37–43. doi:10.1023/A:1016611230747 PubMedCrossRef

55.

Wartiovaara U et al (1998) Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80:171–175PubMed

56.

Rafii S, Psaila B, Butler J, Jin DK, Lyden D (2008) Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 28:217–222. doi:10.1161/ATVBAHA.107.151159 PubMedCrossRef

57.

Janowska-Wieczorek A et al (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113:752–760. doi:10.1002/ijc.20657 PubMedCrossRef

58.

Shojaei F et al (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b⁺Gr1⁺ myeloid cells. Nat Biotechnol 25:911–920. doi:10.1038/nbt1323 PubMedCrossRef

59.

Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8:1369–1375. doi:10.1038/ncb1507 PubMedCrossRef

60.

Kaplan RN et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827. doi:10.1038/nature04186 PubMedCrossRef

61.

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78. doi:10.1038/nrc1256 PubMedCrossRef

62.

Koebel CM et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–908. doi:10.1038/nature06309 PubMedCrossRef

63.

Daniel D et al (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017–1028. doi:10.1084/jem.20021047 PubMedCrossRef

64.

Muller-Hermelink N et al (2008) TNFR1 signaling and IFN-g signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13:507–518. doi:10.1016/j.ccr.2008.04.001 PubMedCrossRef

65.

Manning EA et al (2007) A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13:3951–3959. doi:10.1158/1078-0432.CCR-07-0374 PubMedCrossRef

66.

Ganss R, Hanahan D (1998) Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 58:4673–4681PubMed

67.

Haniffa MA, Collin MP, Buckley CD, Dazzi F (2009) Mesenchymal stem cells: the fibroblasts’ new clothes? Haematologica 94(2):258–263PubMedCrossRef

68.

Mishira PJ et al (2008) Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68:4331–4339. doi:10.1158/0008-5472.CAN-08-0943 CrossRef

69.

Au P, Tam J, Fukumura D, Jain RK (2008) Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 111:4551–4558. doi:10.1182/blood-2007-10-118273 PubMedCrossRef

70.

de Palma M et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211–226. doi:10.1016/j.ccr.2005.08.002 PubMedCrossRef

71.

Bexell D et al (2009) Bone marrow multipotent mesenchymal stromal cells act as pericyte-like migratory vesicles in experimental gliomas. Mol Ther 17:183–190. doi:10.1038/mt.2008.229 PubMedCrossRef

72.

Beckermann BM et al (2008) VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99:622–631. doi:10.1038/sj.bjc.6604508 PubMedCrossRef

73.

Studeny M et al (2004) Mesenchymal stem cells: potential precursors for tumor stromal and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593–1603PubMedCrossRef

74.

Capillo M et al (2003) Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9:377–382PubMed

75.

Suriano R et al (2008) 17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. Cancer Res 68:6038–6042. doi:10.1158/0008-5472.CAN-08-1009 PubMedCrossRef

Titel: Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature
verfasst von: G-One Ahn
J. Martin Brown
Publikationsdatum: 01.06.2009
Verlag: Springer Netherlands
Erschienen in: Angiogenesis / Ausgabe 2/2009
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-009-9135-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Semaphorins and tumor angiogenesis

Endogenous endothelial cell signaling systems maintain vascular stability

Fibronectins in vascular morphogenesis

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis